Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda , sending its ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment ...

Both mRNA vaccines have been tweaked to target the KP.2 strain of COVID-19, which is a slightly more recent version of the virus than what Novavax targets, which is KP.2's "parent" JN.1.

The Novavax vaccine would be authorized for use in adults only in two doses. The company submitted a request, which the FDA is considering, to provide the same vaccine as a booster dose.

In this Feb. 26, 2022 file photo a kidney dish with syringes containing the Novavax COVID-19 vaccine sits in a refrigerator ready for use at a vaccination center in Prisdorf, Germany, Feb. 26, 2022.

Novavax’s recent application for licensing its Covid-19 vaccine in Australia, Canada, and the UK hasn’t gained much traction in the US media. This is odd, given that the vaccine could not only ...

Novavax, a small biotech company in Maryland, garnered attention June 18 when it announced its vaccine candidate is more than 90% effective overall and 100% effective at preventing moderate to ...

Even with two other vaccines authorized, Novavax is having no trouble recruiting volunteers for its U.S. trial. If all goes well, the U.S. could see 110 million doses in June.

Novavax, one of five COVID vaccine-makers to receive large federal grants, says its shots are more than 90% effective against infection.